Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Blood

Volumn 126, Issue 24, 2015, Pages 2578-2584

  Zugmaier, Gerhard ^a   Gökbuget, Nicola ^b   Klinger, Matthias ^a   Viardot, Andreas ^c   Stelljes, Matthias ^d   Neumann, Svenja ^e   Horst, Heinz A ^e   Marks, Reinhard ^f   Faul, Christoph ^g   Diedrich, Helmut ^h   Reichle, Albrecht ⁱ   Brüggemann, Monika ^e   Holland, Chris ^j   Schmidt, Margit ^a   Einsele, Hermann ^k   Bargou, Ralf C ^k   Topp, Max S ^k  

^a Amgen Research GmbH   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF REGENSBURG   (Germany)

^j AMGEN INC   (United States)

^k UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; CYTARABINE; FILGRASTIM; FLUDARABINE; HEMOGLOBIN; IDARUBICIN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BLOOD CELL COUNT; BONE MARROW; BRAIN DISEASE; CANCER SURVIVOR; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONVULSION; CYTOKINE RELEASE SYNDROME; DRUG WITHDRAWAL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM CARE; LONG TERM SURVIVAL; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ALLOGRAFT; BLOOD; DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY; SECRETION (PROCESS); STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTICENTER STUDIES AS TOPIC; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 84951267818     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-649111     Document Type: Article

References (15)

1. Tavernier E, Boiron JM, Huguet F, et al; GETLALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914.
2. Oriol A, Vives S, Hernández-Rivas JM, et al; Programa Español de Tratamiento en Hematologia Group. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589-596.
3. Fielding AK, Richards SM, Chopra R, et al; Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109(3):944-950.
4. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010;116(24):5568-5574.
5. Gökbuget N, Stanze D, Beck J, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-2041.
6. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011; 317(9):1255-1260.
7. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134-4140.
8. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, singlearm, phase 2 study. Lancet Oncol. 2015;16(1): 57-66.
9. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18): 2493-2498.
10. National Cancer Institute. NCI common terminology criteria for adverse events (CTCAE) v4.0.Bethesda, MD: National Cancer Institute; 2010. NIH publication no. 09-5.
11. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891):974-977.
12. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35-44.
13. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119(15):2728-2736.
14. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
15. Topp MS, Stelljes M, Zugmaier G, et al. Reexposure to blinatumomab after CD19-positive relapse: experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL) [abstract]. J Clin Oncol. 2015;33(Suppl). Abstract 7051.